Skip to main content

Michael Lotze M.D., FACS

  • Senior Advisor, UPMC Enterprises 
  • Professor, Department of Surgery
  • Professor, Department of Bioengineering
  • Editor in Chief, Journal for Immunotherapy of Cancer (JITC) 
  • PMI Graduate Faculty

    Education & Training

  • M.D., Northwestern University (1974)
Representative Publications

1: Murthy P, Zenati MS, AlMasri SS, DeSilva A, Singhi AD, Paniccia A, Lee KK, 

Simmons RL, Bahary N, Lotze MT, Zureikat AH. Impact of Recombinant Granulocyte 

Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected 

Pancreatic Cancer. J Natl Compr Canc Netw. 2023 Dec 27;22(1D):e237070. doi: 

10.6004/jnccn.2023.7070. PMID: 38150819. 

2: Perales-Linares R, Leli NM, Mohei H, Beghi S, Rivera OD, Kostopoulos N, 

Giglio A, George SS, Uribe-Herranz M, Costabile F, Pierini S, Pustylnikov S, 

Skoufos G, Barash Y, Hatzigeorgiou AG, Koumenis C, Maity A, Lotze MT, Facciabene 

A. Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune 

Evasion and Immunotherapy Resistance. Cancer Res. 2023 Nov 1;83(21):3562-3576. 

doi: 10.1158/0008-5472.CAN-22-2499. PMID: 37578274; PMCID: PMC10618737. 

3: Tang D, Kang R, Zeh HJ, Lotze MT. The multifunctional protein HMGB1: 50 years 

of discovery. Nat Rev Immunol. 2023 Dec;23(12):824-841. doi: 

10.1038/s41577-023-00894-6. Epub 2023 Jun 15. PMID: 37322174. 

4: Ivey AD, Matthew Fagan B, Murthy P, Lotze MT, Zeh HJ, Hazlehurst LA, 

Geldenhuys WJ, Boone BA. Chloroquine reduces neutrophil extracellular trap (NET) 

formation through inhibition of peptidyl arginine deiminase 4 (PAD4). Clin Exp 

Immunol. 2023 Mar 24;211(3):239-247. doi: 10.1093/cei/uxad005. PMID: 36655514; 

PMCID: PMC10038322. 

5: Carleton N, Nasrazadani A, Gade K, Beriwal S, Barry PN, Brufsky AM, Bhargava 

R, Berg WA, Zuley ML, van Londen GJ, Marroquin OC, Thull DL, Mai PL, Diego EJ, 

Lotze MT, Oesterreich S, McAuliffe PF, Lee AV. Personalising therapy for early- 

stage oestrogen receptor-positive breast cancer in older women. Lancet Healthy 

Longev. 2022 Jan;3(1):e54-e66. doi: 10.1016/s2666-7568(21)00280-4. Epub 2022 Jan 

5. PMID: 35047868; PMCID: PMC8765742. 

6: Cuyler J, Murthy P, Spada NG, McGuire TF, Lotze MT, Xie XQ. 

Sequestsome-1/p62-targeted small molecules for pancreatic cancer therapy. Drug 

Discov Today. 2022 Jan;27(1):362-370. doi: 10.1016/j.drudis.2021.09.011. Epub 

2021 Sep 27. PMID: 34592447.   

7: Mohindroo C, Hasanov M, Rogers JE, Dong W, Prakash LR, Baydogan S, Mizrahi 

JD, Overman MJ, Varadhachary GR, Wolff RA, Javle MM, Fogelman DR, Lotze MT, Kim 

MP, Katz MHG, Pant S, Tzeng CD, McAllister F. Antibiotic use influences outcomes 

in advanced pancreatic adenocarcinoma patients. Cancer Med. 2021 

Aug;10(15):5041-5050. doi: 10.1002/cam4.3870. Epub 2021 Jul 11. PMID: 34250759; 

PMCID: PMC8335807. 

8: Mendonça Gorgulho C, Krishnamurthy A, Lanzi A, Galon J, Housseau F, Kaneno R, 

Lotze MT. Gutting it Out: Developing Effective Immunotherapies for Patients With 

Colorectal Cancer. J Immunother. 2021 Feb-Mar 01;44(2):49-62. doi: 

10.1097/CJI.0000000000000357. PMID: 33416261; PMCID: PMC8092416. 

9: Soloff AC, Jones KE, Powers AA, Murthy P, Wang Y, Russell KL, Byrne-Steele M, 

Lund AW, Yuan JM, Monaco SE, Han J, Dhupar R, Lotze MT. HMGB1 Promotes Myeloid 

Egress and Limits Lymphatic Clearance of Malignant Pleural Effusions. Front 

Immunol. 2020 Sep 4;11:2027. doi: 10.3389/fimmu.2020.02027. PMID: 33013860; 

PMCID: PMC7498625. 

10: Brufsky A, Lotze MT. Ratcheting down the virulence of SARS-CoV-2 in the 

COVID-19 pandemic. J Med Virol. 2020 Nov;92(11):2379-2380. doi: 

10.1002/jmv.26067. Epub 2020 Jun 3. PMID: 32458475; PMCID: PMC7283725. 

11: Zeh HJ, Bahary N, Boone BA, Singhi AD, Miller-Ocuin JL, Normolle DP, 

Zureikat AH, Hogg ME, Bartlett DL, Lee KK, Tsung A, Marsh JW, Murthy P, Tang D, 

Seiser N, Amaravadi RK, Espina V, Liotta L, Lotze MT. A Randomized Phase II 

Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and 

Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Clin Cancer Res. 2020 

Jul 1;26(13):3126-3134. doi: 10.1158/1078-0432.CCR-19-4042. Epub 2020 Mar 10. 

PMID: 32156749; PMCID: PMC8086597. 

Research Interests
  • T and DC interactions in tumor immunity
  • Mitochondrial biology in immunity 
  • Gamma Delta T cells 
  • T and B cell repertoire (the adaptome) 
  • Damage associated molecular pattern molecules including HMGB1 and its receptors, RAGE and TLR4 
  • Measures of DNA as a DAMP in cancer 
  • Redox regulation of immunity 
  • Pancreatic cancer 

Dr. Lotze's primary area of research is in tumor immunology, particularly the role of cellular therapy using dendritic cells and T cells. His current research interests include repertoire analysis in the clinic (T and B cells), the role of gamma delta T cells, the role of autophagy, the nuclear protein high molecular group B1 [HMGB1] and other Damage Associated Molecular Pattern Molecules [DAMPs] in tissue injury, repair, and cancer. His current major clinical interest is in gastrointestinal malignancies, especially pancreatic cancer.